Multiple Sclerosis - Cleveland Clinic

medication vials, syringes, tablets and capsules on a tabletop

April 14, 2025/Neurosciences/Multiple Sclerosis

Early Intensive or Escalation Therapy for Relapsing-Remitting Multiple Sclerosis?

Extension of DELIVER-MS trial will clarify long-term clinical effects of dueling treatment philosophies

hand pointing at brain scans on a computer monitoring

April 9, 2025/Neurosciences/Multiple Sclerosis

Disability Progression Slowed for First Time in Nonrelapsing Secondary Progressive Multiple Sclerosis

BTK inhibitor tolebrutinib shows positive results in phase 3 HERCULES trial

middle-aged woman with surgical mask looking out a window

January 23, 2025/Neurosciences/Multiple Sclerosis

Registry Studies Reassure on Impact of COVID-19 in People With MS

No effect on symptom severity or disability, and low prevalence of long COVID

November 20, 2024/Behavioral Health/Podcasts

Navigating Behavioral Health Challenges in Patients With Multiple Sclerosis (Podcast)

Using multidisciplinary care to address mood changes, mitigate daily stressors

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

3D maps of T2 MRIs in postmortem multiple sclerosis brains

November 7, 2024/Neurosciences/Multiple Sclerosis

Disability Can Be Independent of Cerebral White Matter Demyelination in Progressive MS

MRI classifier identifies a subset of patients with disease marked by cortical atrophy, not demyelination

dr. daniel ontaneda against a decorative background

October 2, 2024/Neurosciences/Podcast

Takeaways From the New Diagnostic Criteria for Multiple Sclerosis (Podcast)

A co-author explains some of the key McDonald criteria revisions

middle-aged woman leaning against porch railing

September 20, 2024/Neurosciences/Multiple Sclerosis

First Evidence of Delayed Disability Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial

September 19, 2024/Neurosciences/Multiple Sclerosis

Let’s Move From Categorizing MS by Clinical Phenotype to Underlying Disease Mechanisms

Meaningful characterization is critical to advancing research and care, review authors contend

heads of an adolescent boy and man in his fifties

September 17, 2024/Neurosciences/Multiple Sclerosis

When Multiple Sclerosis Is Suspected in Patients Under 18 or Over 50

Guidance from international committee on differential diagnoses and diagnostic approach

neurons, axons and synapses in the brain

September 5, 2024/Neurosciences/Research

A Case Study in Neurotherapeutic Clinical Trial Design and Conduct

New phase 1 trial showcases Neurological Institute’s interdisciplinary study capabilities